MiroBio aims to advance therapies that address the immune imbalance that leads to autoimmune diseases. Those therapies—checkpoint agonist antibodies—are designed to precisely restore a balanced immune response and prevent the body from attacking its own cells, potentially providing durable remission from complex and often chronic immune-mediated conditions. Miro aims to capitalize on the role of checkpoint pathways as powerful regulators of immune cell function . . .